Physician profile
Jay Wang
NPI 1952509606
$125,120.85
in general payments reported to CMS, 2019-2025
96 companies · $15K in 2025
The $15K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $20K · 2021: $15K · 2022: $14K · 2023: $13K · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $9,413 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,866 · Travel and Lodging: $3,047 · Honoraria: $1,275 · Education: $17.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,031.53 |
| Consulting Fee | $9,412.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,866.00 |
| Travel and Lodging | $3,046.95 |
| Honoraria | $1,275.00 |
| Education | $17.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14,088.04 | 2019-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals Lp | $12,200.54 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Eisai INC. | $8,024.10 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $7,509.94 | 2021-2025 | Zepzelca |
| Janssen Biotech, INC. | $7,016.43 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Celgene Corporation | $6,125.13 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Deciphera Pharmaceuticals INC. | $6,048.47 | 2021-2025 | Qinlock, Tgct |
| Rigel Pharmaceuticals, INC. | $4,495.56 | 2019-2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $4,292.01 | 2019-2025 | |
| Abbvie INC. | $3,742.68 | 2019-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $3,606.08 | 2020-2025 | Tazverik, Onivyde, Somatuline Depot |
| Aurobindo Pharma USA, INC. | $3,602.15 | 2019-2020 | |
| Verastem, INC. | $3,281.41 | 2019 | |
| Genzyme Corporation | $3,024.87 | 2019-2025 | |
| Array Biopharma INC | $2,882.55 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
Show all 96 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,504.58 | 2019-2025 | Opdivo, Opdualag |
| Acceleron Pharma, INC. | $2,469.91 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $2,291.52 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $2,263.48 | 2019-2025 | Alunbrig, Ninlaro, Hyqvia |
| Kite Pharma, INC. | $1,914.46 | 2020-2024 | Yescarta |
| Pfizer INC. | $1,881.82 | 2019-2025 | |
| Clovis Oncology, INC. | $1,693.46 | 2019-2020 | |
| Cti Biopharma Corp. | $1,362.04 | 2022-2023 | Vonjo |
| Epizyme, INC. | $1,350.76 | 2021-2023 | Tazverik |
| Incyte Corporation | $1,203.50 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Aveo Pharmaceuticals, INC. | $1,183.29 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $1,044.73 | 2019-2025 | Polivy, Lunsumio, Alecensa |
| Adaptive Biotechnologies Corporation | $982.02 | 2020-2023 | Clonoseq |
| Lilly USA, LLC | $935.11 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $813.73 | 2019-2025 | Libtayo |
| Daiichi Sankyo INC. | $779.51 | 2020-2025 | Enhertu, Datroway |
| Amgen INC. | $644.22 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $606.24 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $602.60 | 2019-2023 | Padcev, Adcetris, Tivdak |
| Alexion Pharmaceuticals, INC. | $516.48 | 2019-2025 | Ultomiris |
| Foundation Medicine, INC. | $492.85 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $490.28 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $488.49 | 2019-2025 | Xtandi, Padcev, Xospata |
| Gilead Sciences, INC. | $471.22 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $445.33 | 2020-2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $445.18 | 2019-2025 | |
| Sobi, INC | $298.05 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $268.98 | 2022-2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.28 | 2019-2024 | Gilotrif |
| Puma Biotechnology, INC. | $256.37 | 2019-2025 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Exelixis INC. | $241.54 | 2019-2025 | Cabometyx |
| Kyowa Kirin, INC. | $217.02 | 2020-2025 | Poteligeo |
| Beone Medicines USA, INC. | $208.06 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $207.26 | 2023-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $204.83 | 2020-2025 | Myrisk |
| Intuitive Surgical, INC. | $192.06 | 2024 | |
| Dova Pharmaceuticals | $154.68 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $145.36 | 2023-2025 | Monoferric |
| Servier Pharmaceuticals LLC | $140.38 | 2021-2024 | |
| Mirati Therapeutics, INC. | $131.11 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $128.95 | 2023-2025 | Besremi |
| Agios Pharmaceuticals, INC. | $121.70 | 2019-2024 | Pyrukynd |
| Karyopharm Therapeutics INC. | $117.28 | 2020-2025 | Xpovio |
| Adc Therapeutics America, INC. | $107.13 | 2021-2025 | |
| G1 Therapeutics, INC. | $105.86 | 2022-2023 | Cosela |
| Myovant Sciences INC. | $105.59 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $97.56 | 2019-2025 | Provenge |
| Acrotech Biopharma INC. | $96.54 | 2021-2025 | Beleodaq |
| Tersera Therapeutics LLC | $93.72 | 2022-2023 | Zoladex |
| Sumitomo Pharma America, INC. | $92.01 | 2023-2025 | Orgovyx |
| Eusa Pharma (US) LLC | $73.44 | 2019-2021 | |
| Emd Serono, INC. | $69.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $66.77 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $64.32 | 2020-2024 | Xarelto |
| Morphosys, US INC. | $61.70 | 2023-2024 | Monjuvi |
| Geron Corporation | $58.49 | 2025 | Rytelo |
| Amag Pharmaceuticals, INC. | $48.53 | 2019-2021 | |
| Genmab U.S., INC. | $46.91 | 2023-2024 | Epkinly |
| Syndax Pharmaceuticals, INC. | $46.79 | 2025 | |
| Iovance Biotherapeutics, INC. | $44.93 | 2025 | Amtagvi |
| Blueprint Medicines Corporation | $43.07 | 2020 | |
| Sirtex Medical INC | $40.38 | 2020 | |
| Heron Therapeutics, INC. | $34.63 | 2019-2022 | |
| Coherus Oncology, INC. | $32.99 | 2021-2022 | |
| Secura Bio, INC. | $32.55 | 2020-2021 | |
| Springworks Therapeutics, INC. | $27.49 | 2025 | Ogsiveo |
| Recordati_rare_diseases_inc. | $25.91 | 2025 | Enjaymo |
| Janssen Scientific Affairs, LLC | $24.87 | 2019 | |
| Organogenesis INC. | $24.84 | 2022 | |
| Portola Pharmaceuticals, LLC | $22.14 | 2019 | |
| Immunomedics, INC. | $20.61 | 2020 | |
| Tg Therapeutics, INC. | $20.53 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.31 | 2022 | |
| Argenx US, INC. | $19.90 | 2025 | Vyvgart |
| Sanofi-Aventis U.S. LLC | $19.40 | 2021 | |
| Partner Therapeutics, INC. | $18.57 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.75 | 2025 | Danziten |
| Shire North American Group INC | $13.49 | 2019 | |
| Emmaus Medical, INC. | $13.30 | 2019 | |
| Veracyte, INC. | $4.01 | 2020 |
Drugs and devices associated with these payments
Zepzelca $7,394Qinlock $5,964Inqovi $3,118Tazverik $2,880Alunbrig $1,700Keytruda $1,001Calquence $854Enhertu $663Libtayo $598Imfinzi $584Xtandi $409Jakafi $379Brukinsa $375Lenvima $339Lynparza $330Reblozyl $329Tukysa $315Monjuvi $311Opdualag $307Ibrance $290Pluvicto $290Opdivo $267Verzenio $262Ultomiris $251Jaypirca $250Kisqali $243Orgovyx $240Talzenna $235Braftovi $224Ninlaro $216Elrexfio $212Orserdu $207Mektovi $203Ojjaara $198Adcetris $193Da Vinci Surgical System $192Inlyta $190Venclexta $188Cabometyx $188Padcev $182Trodelvy $178Polivy $176Imbruvica $170Lorbrena $165Scemblix $160Vonjo $160Poteligeo $153Pemazyre $152Fabhalta $150Lonsurf $149Monoferric $145Rybrevant $143Erleada $139Stivarga $133Vitrakvi $133Krazati $131Nubeqa $130Besremi $129Onivyde $125Bosulif $120Piqray $117Epkinly $110Pomalyst $109Sarclisa $106Doptelet $106Xalkori $106Jemperli $105Darzalex $105Hyqvia $101Myrisk $101Tibsovo $98.18Fruzaqla $97.13Tavalisse $90.84Rezlidhia $90.84Tasigna $89.98Datroway $86.94Xpovio $82.86Tevimbra $82.34Gilotrif $82.17Talvey $81.78Welireg $80.90Fotivda $76.35Zejula $74.25Idhifa $73.29Niktimvo $72.69Tivdak $69.25Lutathera $67.31Yescarta $62.49Vonvendi $62.38Xospata $61.70Nerlynx $60.64Rytelo $58.49Pyrukynd $57.79Enjaymo $56.30Retevmo $55.74Zynyz $55.18Promacta $55.00Cosela $54.53Bavencio $53.71Lunsumio $52.49
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.